Replimune Group Inc.已通过一项章程修正案,将其授权普通股数量提升至300,000,000股。该举措已正式备案于美国证券交易委员会(SEC)的公开文件中。
Replimune Group Inc.已通过一项章程修正案,将其授权普通股数量提升至300,000,000股。该举措已正式备案于美国证券交易委员会(SEC)的公开文件中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.